Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021.

Martins, Alexander C; Oshiro, Mariana Y; Albericio, Fernando; de la Torre, Beatriz G; Pereira, Gustavo José V; Gonzaga, Rodrigo V

Martins, Alexander C; Oshiro, Mariana Y; Albericio, Fernando; de la Torre, Beatriz G; Pereira, Gustavo José V; Gonzaga, Rodrigo V.

Afiliação

Martins AC; School of Health Sciences, UAM, Universidade Anhembi-Morumbi, São Paulo 03101-001, Brazil.
Oshiro MY; School of Health Sciences, UAM, Universidade Anhembi-Morumbi, São Paulo 03101-001, Brazil.
Albericio F; School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa.
de la Torre BG; CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain.
Pereira GJV; KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.
Gonzaga RV; School of Health Sciences, UAM, Universidade Anhembi-Morumbi, São Paulo 03101-001, Brazil.

Biomedicines ; 10(9)2022 Sep 19.

Article em En | MEDLINE | ID: mdl-36140426

Palavras-chave

FDA approvals; Food and Drug Administration; antibodydrug conjugate; biological drugs; first global approval; monoclonal antibody

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Biomedicines Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google